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Background: The efﬁcacy and safety of thrombolytic therapy in stroke depend on multiple
factors. The aim of this study was to evaluate the signiﬁcance of atrial ﬁbrillation the
prognosis in terms of the functional status in patients with stroke treated with intravenous
thrombolysis. An additional aim was also to assess the potential signiﬁcance of reduced
ejection fraction (EF) and enlarged left atrium (LA) of the heart for the prognosis in patients
with stroke who underwent thrombolytic therapy.
Methodology: A prospective study involved enrollment of 222 patients, mean age of 72 years
with ﬁrst-in-life ischemic stroke. In all participants there were realized procedures as
follows: neurological status before administering rt-PA (NIHSS), selected echocardiographic
parameters, functional status on the 14th day from the onset (mRankin scale) and analysis
the bleeding events.
Results: Atrial ﬁbrillation was signiﬁcantly more frequent in women than men; females had
higher CHA2DS2VASc scores and heavier neurological conditions on day 1 of stroke. Two
independent factors for poor prognosis (3–5 points by mRankin) were found: the NIHSS score
and the CHA2DS2VASc score ≥3. We identiﬁed 2 independent factors for death within 14
days from the onset: the result by NIHSS and the EF. The NIHSS score turned out to be the
only independent predictor of hemorrhage during hospitalization: RR 1.19; CI [1.06–1.33];
p = 0.003; p for model = 0.0025.
Conclusions: The presence of atrial ﬁbrillation worsens the patient's prognosis in terms of the
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Higher NIHSS and CHA2DS2VASc scores and reduced EF in patients with stroke treated
with thrombolysis are the predictors of unfavorable short-term prognosis.
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The efﬁcacy and safety of thrombolytic therapy in stroke
depend on multiple factors. Although the potential impor-
tance of atrial ﬁbrillation (AF) for the above parameters has
been the subject of several studies, a disparity between their
results prevents us from formulating a clear conclusion. It is
likely that both the type of atrial ﬁbrillation and coexisting
structural and functional heart disorders accompanying
arrhythmia may play a role regardless of the electromechani-
cal and hemodynamic effects associated with AF. Given the
prevalence of AF among patients with stroke, one should
deﬁne the meaning of arrhythmia for the effects of thrombo-
lytic therapy, as it may affect the selection of patients who
could obtain the best beneﬁts from such treatment.
The aim of this study was to evaluate the signiﬁcance of AF
for the prognosis in terms of the functional status in patients
with stroke treated with intravenous thrombolysis. An
additional aim was also to assess the potential signiﬁcance
of reduced ejection fraction (EF) and enlarged left atrium (LA)
of the heart for the prognosis in patients with stroke who
underwent thrombolytic therapy.
2. Methodology
A prospective study (period: 2014–2015) involved enrollment of
222 patients, mean age of 72 years (39–89; 107 women, 155
men); the subjects were patients with ﬁrst-in-life stroke
diagnosed by the WHO's clinical criteria, and an ischemic
focus in the brain present in neuroimaging (CT and/or MRI of
the head) [1]. All the subjects received recombinant tissue
plasminogen activator (rt-PA) intravenous within 4.5 h from
the disease onset, which was in accordance with the eligibility
criteria for thrombolytic therapy [2]. The study excluded the
patients who underwent endovascular treatment due to
cerebral stroke – the aim of the study was to evaluate the
importance of selected parameters for the prognosis of
patients treated homogeneously (without the effect of general
anesthesia used in approximately half of the patients given
endovascular treatment in our center).
All the patients included in the study were examined in
terms of the following:
 the patient's age at the time of ﬁrst-ever ischemic stroke;
 presence of atrial ﬁbrillation (valvular and non-valvular); AF
due to reasons other than valvular heart disease was
considered as non-valvular atrial ﬁbrillation;
 presence of conditions/comorbidities such as arterial hy-
pertension, diabetes and lipid disorders; >70% of athero-
sclerotic carotid artery stenosis (ipsilaterally to the ischemic
focus in the brain); neurological status evaluated before administering rt-PA
according to NIHSS (National Institutes of Health Stroke
Scale) [3];
 anticoagulant therapy conducted before the stroke onset;
 result by the CHA2DS2VASc scale;
 selected echocardiographic parameters: the presence of
thrombus in the left atrium, reduced EF (<55%) and enlarged
left atrium (LA > 3.8 cm for women and >4.0 cm for men
relative to body surface area);
 intracranial bleeding
 extracranial bleeding: from the nasal cavities, gastrointesti-
nal tract, genital and urinary tract or from other areas
requiring substitution with 2 units of packed red blood cells;
 functional status on the 14th day from the onset according to
mRankin scale [4].
The diagnosis of hypertension was consistent with the
recommendation by the Polish Society of Cardiology [5]; diabetes
mellitus was diagnosed according to the criteria by the Polish
Diabetes Association (2013) [6]; dyslipidemia was deﬁned as total
cholesterol serum level >200 mg/dl (>5.18 mmol/l); or LDL-
cholesterol serum level >100 mg/dl (2.59 mmol/l); or HDL-
cholesterol serum level <35 mg/dl (0.91 mmol/l); or triglycerides
serum level >135 mg/dl (1.53 mmol/l).
The degree of common carotid artery stenosis and/or
internal carotid stenosis was rated according to the NASCET
criteria [7].
Patients were divided into 2 groups depending on the
presence of AF (present vs. absent) and depending on the
CHA2DS2VASc result (<3 vs. ≥3 points); results were compared
in parallel groups.
The type of intracranial bleeding was determined according
to the ECASS I and II deﬁnition (European Cooperative Acute
Stroke Study) [8,9].
Multivariate analysis was performed in order to determine
independent factors for unfavorable prognosis deﬁned as
obtaining 3–5 points on mRankin scale by a patient on their
14th day after stroke or as the patient's death within 14 days of
onset. The analysis included the following parameters: age
(also in subgroups: <65 years and ≥65 years), sex (including
subgroups: <65 years and ≥65 years), arterial hypertension,
diabetes, atrial ﬁbrillation (valvular and non-valvular AF), lipid
disorders, stenosis of the carotid artery >70%, NIHSS,
CHA2DS2VASc ≥3, EF < 55%, enlargement of LA and bleeding
during 14-days hospitalization.
3. Results
Demographic and selected clinical patients' parameters are
presented in Table 1.
Table 1 – Characteristics of patients.
Patients, n 222
Age, mean (median, range) 69.7  10.8 (72; 39–89)
F/M 107/115 (48.1%/51.9%)
Arterial hypertension, n (%) 175 (78.8)
Diabetes mellitus, n (%) 74 (33.3)
Atrial ﬁbrillation, n (%) 81 (36.4)
de novo, n (%) 8 (9.8)
Valvular AF 42 (51.8)
Carotid artery stenosis >70%, n (%) 67 (30.1)
Lipid disorders, n (%) 53 (23.8)
Past and documented myocardial
infarction, n (%)
37 (16.66)
CHA2DS2VASc, mean (range) 4.05 (2–9)
NIHSS, mean (range) 8.46 (4–25)
Previous anticoagulant therapy, n (%) 32 (14.5)
F – female, M – male, NIHSS – National Institutes of Health Stroke
Scale.
Table 2 – Comparison of selected parameters between the
group of patients with AF and patients without AF.
AF AF+ p
n = 141 n = 81
F 59 (41.8%) 48 (59.3%) 0.0124*
Age 69  12.2 71  9.4 0.782#
EF 52.7  7.2 44.8  9.0 0.0000#
LA size 40.3  3.0 42.8  3.6 0.0000#
CHA2DS2VASc 3.7  1.8 4.4  1.9 0.0025+
CHA2DS2VASc ≥3 75 (53.2%) 61 (75.3%) 0.0011+
NIHSS 7.3  4.9 9.6  5.5 0.0016+
mRankin 2.8  1.9 3.7  2.0 0.0012+
mRankin 3–5 79 (56.0%) 58 (71.6%) 0.0215*
Death 10 (7.1%) 17 (21.0%) 0.0023*
Iatrogenic hemorrhage
including
3 (2.1%) 6 (7.4%) 0.0549*
intracranial bleeding 3 (2.1%) 2 (2.4%) 0.0487*
F – female, AF – patients without atrial ﬁbrillation, AF+ – patients
with atrial ﬁbrillation, EF – ejection fraction, LA – left atrium, NIHSS
– National Institutes of Health Stroke Scale
* Chi2.
# Student test.
+ U Mann–Whitney test.
Table 3 – Comparison of selected parameters between the group
CHA2DS2VASc score ≥3.
CHA2DS2VASc < 3
n = 86
F 31 (36.0%) 
Age 68  11.9 
AF 20 (23.3%) 
Valvular AF 6 (7.0%) 
EF 52.0  7.2 
LA size 40.5  3.6 
NIHSS 7.0  5.3 
Rankin 2.5  1.9 
Rankin 3–5 41 (47.7%) 
Death 6 (7.0%) 
Iatrogenic hemorrhage 5 (5.8%) 
F – female, AF – atrial ﬁbrillation, EF – ejection fraction, LA – left atrium,
* Chi2.
# Student test.
+ U Mann–Whitney test.
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and those with no arrhythmia found a number of statistically
signiﬁcant differences in demographic, echocardiographic and
clinical parameters, as shown in Table 2.
In the group of patients with CHA2DS2VASc score ≥3, there
were signiﬁcantly more females, patients with atrial ﬁbrilla-
tion, including valvular AF, and patients with unfavorable
clinical and echocardiographic parameters compared to
patients with CHA2DS2VASc score <3, as shown in Table 3.
Differences in the incidence of hemorrhage during hospitali-
zation, and death within 14 days of the onset of stroke, were
not statistically signiﬁcant.
Atrial ﬁbrillation was signiﬁcantly more frequent in women
than men; females had higher CHA2DS2VASc scores and
heavier neurological conditions on day 1 of stroke. There were
no signiﬁcant differences in the consequences of stroke
(according to mRankin) in a 14-day observation (Table 4).
Two independent factors for poor prognosis (3–5 points by
mRankin) were found: the NIHSS score and the CHA2DS2VASc
score ≥3 (Table 5).
We identiﬁed 2 independent factors for death within 14
days from the onset: the result by NIHSS and the EF (Table 6).
The NIHSS score turned out to be the only independent
predictor of hemorrhage during hospitalization: RR 1.19; CI
[1.06–1.33]; p = 0.003; p for model = 0.0025.
4. Discussion
Age, diabetes and stroke within the preceding 3 months are
recognized factors that modify the effectiveness of rt-PA in
acute cerebral stroke. Previous observations do not allow for a
clear identiﬁcation of the importance of AF for the effect of
thrombolytic therapy, especially in the acute phase of disease.
Results of several studies suggest a worse clinical effect and
lower safety of rt-PA application in patients with AF; however,
it is difﬁcult to draw consistent conclusions due to the
differences in study protocols [10–13]. It has been indicated
that there was a lower percentage for the recanalization of
arteries in the patients with AF treated with rt-PA compared to of patients with CHA2DS2VASc score <3 and patients with
CHA2DS2VASc ≥3
n = 136
p
76 (55.9%) 0.0040*
70  10.1 0.692#
61 (44.9%) 0.0011*
36 (26.5%) 0.0003*
48.4  9.3 0.0021#
41.6  3.4 0.0143#
8.9  5.1 0.0037+
3.5  1.9 0.0005+
96 (70.6%) 0.0006*
21 (15.4%) 0.0602*
4 (2.9%) 0.2904*
 NIHSS – National Institutes of Health Stroke Scale.
Table 4 – Comparison of selected parameters depending
on the patient's sex.
M
n = 115
F
n = 107
p
AF 33 (28.7%) 48 (44.9%) 0.0124*
Age 68  4.4 72  2.6 0.167#
Valvular AF 17 (14.8%) 25 (23.4%) 0.1028*
EF 48.7  8.9 50.9  8.4 0.0608#
LA size 41.1  3.2 41.3  3.8 0.6921#
CHA2DS2VASc 3.6  1.6 4.3  2.0 0.0093+
CHA2DS2VASc ≥3 60 (52.2%) 76 (71.0%) 0.0040*
NIHSS 7.3  5.1 9.0  5.3 0.0073+
mRankin 2.9  1.9 3.3  2.0 0.2060+
mRankin 3–5 67 (58.3%) 70 (65.4%) 0.2728*
Death 12 (10.4%) 15 (14.0%) 0.4143*
Iatrogenic hemorrhage including 6 (5.2%) 3 (2.8%) 0.3622*
Intracranial bleeding 3 (2.6%) 2 (1.9%) 0.210*
AF – atrial ﬁbrillation, EF – ejection fraction, LA – left atrium, NIHSS
– National Institutes of Health Stroke Scale.
* Chi2.
# Student test.
+ U Mann–Whitney test.
Table 5 – Independent factors for poor prognosis (3–5
points by mRankin).
RR p for factor p for model
NIHSS 1.30 CI [1.19–1.42] 0.0000 0.0000
CHA2DS2VASc ≥3 2.11 CI [1.11–4.02] 0.0220
NIHSS – National Institutes of Health Stroke Scale.
Table 6 – Independent factors for death within 14 days
from the onset.
RR p for factor p for model
NIHSS 1.19 CI [1.10–1.29] 0.0000 0.0000
EF 0.94 CI [0.89–0.98] 0.0087
NIHSS – National Institutes of Health Stroke Scale, EF – ejection
fraction.
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AF obtained worse scores than patients without arrhythmia
(OR for a more favorable outcome: 0.57; 95% CI; 0.38–0.86) [14].
Analysis of the ECASS III trial results also indicates such a
trend; however, there was no statistically signiﬁcant differ-
ence (OR: 0.68; 95% CI; 0.30–1.55) [15]. On the contrary, the
results of the meta-analysis entitled the Virtual International
Stroke Trials Archive (VISTA) do not conﬁrm the negative
impact of AF on the effect of thrombolytic therapy [16].
In the present study, the presence of AF was signiﬁcantly
more often associated with unfavorable prognosis in terms of
the functional status and the effect of death within the ﬁrst 2
weeks of the onset of stroke. It is worth emphasizing that
iatrogenic intracranial bleeding did not modify the results in a
statistically signiﬁcant manner.
Perhaps the group of patients with AF should be regarded as
a relatively heterogeneous due to the AF type; that would
explain the disparity between the results obtained by the
authors. It has been recently stressed that compared to
patients with permanent atrial ﬁbrillation a signiﬁcantly better
prognosis relates to patients with paroxysmal AF [17]. It has
been suggested that the duration of arrhythmia is signiﬁcant
for the formation of thrombus and embolic risk. Moreover,
electromechanical and hemodynamic effect accompanying AF
are probably not the only parameters potentially modifying
the effect of therapy in this group of patients. Structural and
functional heart abnormalities may also play an important
role. In the present study, signiﬁcantly more often it was
patients with AF who had reduced ejection fraction, whichreﬂects the dysfunction of the left ventricle and promotes the
formation of thrombi. Based on the analysis of multiple
variables, it was demonstrated that the presence of moderate
to severe LV systolic dysfunction observed in two-dimensional
echocardiography is an independent echocardiographic factor
for acute embolic incident [18,19]. A signiﬁcant decrease in EF
was demonstrated in patients with cardiogenic and crypto-
genic stroke [20]. The present study also revealed a negative
impact of reduced EF on the course of stroke; low EF reduces
the beneﬁts of thrombolytic therapy. In the present study,
signiﬁcantly more often it was patients with AF who had an
enlarged left atrium. As demonstrated, cardiac systolic or
diastolic dysfunction, arterial hypertension, diabetes, high left
ventricular myocardial index and low left ventricular ejection
fraction are related to LA enlargement [21]. Most of these
conditions are also the risk factors for stroke, and they may
modify its course.
AF with its co-morbidities has a negative impact on the
prognosis for patients with stroke. The most common
comorbidities are heart diseases and atherosclerosis of the
arteries supplying brain structures. In the present study,
patients with AF – compared to those without arrhythmia –
were more often burdened with diseases that increase the risk
of stroke, as expressed by a higher CHA2DS2VASc score used
for stratiﬁcation (4.3  2.0 vs. 3.6  1.6; p = 0.0093).
Age is an independent risk factor both for stroke and AF;
moreover, it is a prognostic factor in patients with stroke. It
was also shown that it has hypercoagulable and prothrombo-
tic effects in patients with AF [22,23]. It is worth noting that
some biochemical and vital parameters as abnormal troponin
or blood glucose concentration, body temperature besides
arterial hypertension and neurological status proved to be an
independent factor of post-stroke disability [24–26]. The
female sex in this study was associated with a worse prognosis
in terms of the post-stroke functional status of patients. Varied
responses to thrombolytic therapy in stroke and post-stroke
prognosis have been repeatedly discussed in the literature.
Despite some disparity in the conclusions, the majority of
investigators believe that the female sex is associated with
more severe consequences of stroke, and that the use of
alteplase (for the beneﬁt of women) eliminates gender-related
differences [27,28].
The present study, just like the VISTA meta-analysis,
presented no signiﬁcant differences in the incidence of
iatrogenic bleeding after rt-PA in patients with AF compared
to patients without arrhythmia. In accordance with the
presented results, increasing the NIHSS value by 1 is related
to a 1.2-fold increased risk of intracranial bleeding. Neurologi-
cal status on the ﬁrst day by NIHSS turned out to be an
independent risk factor for unfavorable prognosis (just like
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 1 5 6 – 1 6 1160reduced EF) and death (again CHA2DS2VASc ≥3 points). A
neurological status estimation based on NIHSS, just like
clinical proﬁle evaluation by CHA2DS2VASc in this group of
patients, is one of the key prognostic parameters for the
functioning of post-stroke patients and for death [16,29,30].
Most probably, there are a few factors related to AF which
modify the acute phase of stroke. Patients with AF may have
some past thrombi that undergo fragmentation under the
inﬂuence of alteplase. It is believed that, compared to the
‘‘hard’’ cholesterol emboli formed with the use of thrombi
deposited on atherosclerotic plaques, those AF-associated
emboli are more susceptible to rt-PA activity.
Structural and functional abnormalities of the heart
accompanying AF most probably are additional decisive
factors for the course of the acute phase of stroke and the
effect of thrombolytic therapy.
5. Limitations of the study
There was no analysis conducted that would consider atrial
ﬁbrillation types or the factors present during hospitalization
as the ones to affect prognosis, e.g. vital or biochemical
parameters, pneumonia.
6. Conclusions
The presence of atrial ﬁbrillation worsens the patient's
prognosis in terms of the functional status and survival
during the acute period of stroke in patients treated with
intravenous thrombolysis.
Higher NIHSS and CHA2DS2VASc scores and reduced EF in
patients with stroke treated with thrombolysis are the
predictors of unfavorable short-term prognosis.
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